Open access peer-reviewed Edited Volume

Renin-Angiotensin Aldosterone System

Samy I. McFarlane

SUNY-Downstate Health Science University

A leading physician-scientist and renowned author and mentor. He has edited several books and authored over 300 publications on diabetes, hypertension, dyslipidemia, cardiovascular disease, and related areas. His work has been among the most read articles with over 10,000 citations in major medical journals.

Covering

Renin-Angiotensin-Aldosterone System Pathogenesis Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Blockers Aldosterone Congestive Heart Failure Type 2 Diabetes Clinical Trials Local Tissue RAAS Angiotensinergic Pathways SARS-CoV-2 Spike Protein Population Studies

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The Renin-Angiotensin-Aldosterone System (RAAS) plays a central role in salt and water homeostasis. It also affects various organ systems including the heart and vasculature, the kidney, and the nervous system. Evidence indicates that angiotensin II has major deleterious effects on vascular tone, insulin sensitivity, markers of inflammation, and thrombosis. RAAS overactivity is implicated in the pathogenesis of serious and commonly encountered disease entities including hypertension, type 2 diabetes, diabetic nephropathy, left ventricular hypertrophy, congestive heart failure, and myocardial infarction.
The major pathogenetic mechanisms resulting from RAAS overactivity include activation of the sympathetic nervous system, endothelial dysfunction, proinflammatory, and procoagulant states.
Emerging from basic science evidence, major clinical trials established the beneficial effects of inhibitors of the different components of RAAS such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), aldosterone antagonists. These effects range from treatment of hypertension, diabetic nephropathy, CHF, as well as improvement of outcomes after myocardial infarction and improvement in glucose homeostasis and prevention of type 2 diabetes with some agents.

In this book, written by a world-renowned scholar, we will address the major concepts and topics related to RAAS activation including the pathogenetic mechanisms underlying the deleterious effects of activated RAAS and the role of local tissue RAAS in various organ systems such as the heart and vasculature, the skeletal muscle, adipose tissues, pancreas and the angiotensinergic pathways in the brain. Cutting-edge information is provided that will address the need for a wide range of readers including a medical student, clinical practitioner, and basic science investigators alike. This book will be bridging the gap between basic science and clinical practice regarding the RAAS system, which is imminently critical and highly relevant to the practice of medicine.

Finally, with data emerging from the COVID-19 pandemic indicating overrepresentation of people with diseases associated with RAAS activation such as hypertension, chronic kidney disease, and diabetes, the role of RAAS activation and RAAS inhibition in the pathogenesis and clinical outcomes in COVID-19 has garnered a great deal of interest. In this book, we will dedicate a chapter addressing this topical and highly critical subject.
 

Publishing process

Book initiated and editor appointed

Date completed: October 29th 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: January 25th 2021

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: April 15th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: June 14th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Samy I. McFarlane

SUNY-Downstate Health Science University

Dr. Samy I. McFarlane, MD, MPH, MBA, FACP is a distinguished teaching professor of Medicine and Endocrinology and an Associate Dean at the College of Medicine, State University of New York, Downstate Health Science University, USA. He has extensive experience in clinical and translational research and has led the largest center in North America in the landmark diabetes prevention trial, the DREAM trial using the commonly prescribed ACE-inhibitor ramipril. He has edited several books and authored over 300 publications on diabetes, hypertension, dyslipidemia, cardiovascular disease, and related areas. His work has been among the most read articles with over 10,000 citations in major medical journals. He is the Founding Editor-In-Chief for the International Journal of Clinical Research and Trials and has served as the Editor-In-Chief for several other journals. He is a nationally and internationally recognized scholar who served as a member at the National Institute of Health-NIDDK committee (3x 4- year terms) and as a chair of the NIH-NIDDK U01 review committee (thrice). He has received multiple recognitions including Certificate of Special Congressional Recognition and he also served as District President for the American College of Physicians. He is also a well-recognized mentor with some of his trainees serving in leadership positions at the NIH and other major institutions.

View profile

Book chapters authored 3

Books edited 1

Introducing your Author Service Manager

Ms. Sandra Maljavac

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire